Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study

Table 2 False-negative rate of sentinel lymph node biopsy according to radiologic response

Cohort	Subtypes	Treatment response	All patients				cN2–3				cN1
GSH-YCC	HR+ HER2−			ALN+	ALN−	FNR^a		ALN+	ALN−	FNR^a		ALN+	ALN−	FNR^a
		Complete MRI response	SLN+	11	0	31.3% (8.6–54.0)	SLN+	2	0	50.0% (1.0–99.0)	SLN+	9	0	25.0% (0.5–49.5)
			SLN−	5	9		SLN−	2	4		SLN−	3	5
		Non-complete MRI response	SLN+	110	0	20.9% (14.1–27.6)	SLN+	44	0	17.0% (6.9–27.1)	SLN+	66	0	23.3% (14.3–32.2)
			SLN−	29	43		SLN−	9	7		SLN−	20	36

		ALN+	ALN−	FNR^a		ALN+	ALN−	FNR^a		ALN+	ALN−	FNR^a
Complete MRI response	SLN+	6	0	0.0%	SLN+	0	0	0.0%	SLN+	6	0	0.0%
	SLN−	0	24		SLN−	0	11		SLN−	0	13
Non-complete MRI response	SLN+	36	0	33.3% (20.8–45.9)	SLN+	16	0	23.8% (6.0–42.0)	SLN+	20	0	39.4% (22.7–56.1)
	SLN−	18	97		SLN−	5	30		SLN−	13	67

		ALN+	ALN−	FNR^a		ALN+	ALN−	FNR^a		ALN+	ALN−	FNR^a
Complete MRI response	SLN+	26	0	7.1% (0–16.7)	SLN+	14	0	6.7% (0–19.3)	SLN+	12	0	7.7% (0–22.2)
	SLN−	2	19		SLN−	1	4		SLN−	1	15
Non-complete MRI response	SLN+	105	0	11.8% (6.0–17.6)	SLN+	47	0	9.6% (1.6–17.6)	SLN+	58	0	13.4% (5.3–21.6)
	SLN−	14	100		SLN−	5	20		SLN−	9	80

ALN axillary lymph node, cN clinical nodal stage, FNR false negative rate, HER2 human epidermal growth factor receptor 2, HR hormone receptor, MRI magnetic resonance imaging, SLN sentinel lymph node, TNBC triple-negative breast cancer
^aData in parentheses are 95% confidence intervals

ISSN: 1465-542X